Review of Shorter Treatment for Non-severe Tuberculosis in African and Indian Children— Turkova 2022

This is a brief audio review. In the article Shorter Treatment for Non-severe Tuberculosis in African and Indian Children published, 2022 by Turkova and Colleagues, The outcomes and key points are as noted: The 4 month experimental Tuberculosis drug treatment regimen was just as good as the 6 month standard Tuberculosis drug treatment regimen after 6 years of follow up in children with non-severe, drug susceptible tuberculosis In a Randomized control trial, open label, parallel group with 1204 patients who were Patients younger than 16 years old, diagnosed with non severe, but symptomatic, presumably drug susceptible, smear negative tuberculosis in Uganda, Zambia, South Africa, and India.

Turkova A, Wills GH, Wobudeya E, Chabala C, Palmer M, Kinikar A, Hissar S, Choo L, Musoke P, Mulenga V, Mave V, Joseph B, LeBeau K, Thomason MJ, Mboizi RB, Kapasa M, van der Zalm MM, Raichur P, Bhavani PK, McIlleron H, Demers AM, Aarnoutse R, Love-Koh J, Seddon JA, Welch SB, Graham SM, Hesseling AC, Gibb DM, Crook AM; SHINE Trial Team. Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children. N Engl J Med. 2022 Mar 10;386(10):911-922. doi: 10.1056/NEJMoa2104535. PMID: 35263517; PMCID: PMC7612496.